EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access

The Effect of Metformin on Atezolizumab/Bevacizumab Treatment in Patients with Hepatocellular Carcinoma and Diabetes

Andrea Dalbeni, Marco Vicardi, Leonardo A Natola, Alessandra Auriemma, Bernardo Stefanini, Caterina Vivaldi, Piera Federico, Andrea Polloni, Caterina Soldà, Lorenzo Lani, Ingrid Garajová, Stefano Tamberi und 22 weitere

Oncology Research · 2026

DOI: 10.32604/or.2026.073063 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Oncology Research, 2026. Verfasst von Andrea Dalbeni und 33 weiteren Autor:innen. Beteiligte Einrichtung: Unit of General Medicine C, University of Verona and University and Hospital Trust (AOUI) of Verona, Verona, Italy. Hauptthemen laut MEDLINE: Metformin, Carcinoma, Hepatocellular, Liver Neoplasms, Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

The combination of atezolizumab plus bevacizumab (A+B) represents one of the standards first-line treatments for unresectable hepatocellular carcinoma (HCC). Metformin has garnered attention for its potential antitumour and immunomodulatory properties beyond glycaemic control. This study aimed to assess metformin's impact in patients with type 2 diabetes mellitus (T2DM) receiving A+B therapy.

Methods

This retrospective analysis of a prospectively-maintained multicentre database included 523 patients with HCC treated with A+B from the ARTE (Atezolizumab-bevacizumab Real-life Experience for Treatment of Hepatocellular Carcinoma) dataset across 18 Italian centres (May 2020-January 2024). We evaluated objective response rate (ORR), disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and time to progression (TTP) using Cox regression analysis and Inverse Probability of Treatment Weighting (IPTW) to address confounding.

Results

Among 523 patients, 341 (65.2%) did not have diabetes and 182 (34.8%) had T2DM. In the overall population, metformin showed no significant benefit for PFS (HR = 1.15, 95% CI [0.88-1.50], p = 0.316) or OS (HR = 1.28, 95% CI [0.94-1.74], p = 0.124). In the subgroup with T2DM (N = 180), metformin showed no significant benefit for PFS (HR = 1.41, 95% CI [0.97-2.05], p = 0.069), OS (HR = 1.23, 95% CI [0.81-1.86], p = 0.333), or TTP (HR = 0.82, 95% CI [0.53-1.26], p = 0.363). IPTW analysis confirmed these negative findings.

Conclusion

This study found no evidence of improved outcomes with metformin use in patients with HCC in particular with T2DM receiving A+B therapy. Routine metformin use should not be expected to enhance A+B efficacy based on current evidence.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MetforminCarcinoma, HepatocellularLiver NeoplasmsDiabetes Mellitus, Type 2BevacizumabAntineoplastic Combined Chemotherapy ProtocolsHumansAntibodies, Monoclonal, HumanizedFemaleRetrospective StudiesMaleAgedMiddle AgedHypoglycemic Agents

Stichwörter der Autor:innen

Hepatocellular carcinomaatezolizumabbevacizumabimmune checkpoint inhibitorsmetformintype 2 diabetes mellitus

Substanzen

MetforminatezolizumabAntibodies, Monoclonal, HumanizedBevacizumabHypoglycemic Agents

Autor:innen und Institutionen

  • Unit of General Medicine C, University of Verona and University and Hospital Trust (AOUI) of Verona, Verona, Italy.
  • Liver Unit, University of Verona and University and Hospital Trust (AOUI) of Verona, Verona, Italy.
  • Section of Innovation Biomedicine-Oncology Area, University of Verona and University and Hospital Trust (AOUI) of Verona, Verona, Italy.
  • Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.
  • Unit of Medical Oncology 2, Azienda Ospedaliero-Universitaria Pisana, Pisa, Italy.
  • Medical Oncology Unit, Ospedale del Mare, Napoli, Italy.

Zitieren

APA

Dalbeni, A., Vicardi, M., Natola, L. A., Auriemma, A., Stefanini, B., Vivaldi, C., Federico, P., Polloni, A., Soldà, C., Lani, L., Garajová, I., Tamberi, S., De Lorenzo, S., Piscaglia, F., Di Maria, V., Masi, G., Lonardi, S., Brandi, G., Daniele, B., …, & Sacerdoti, D. (2026). The Effect of Metformin on Atezolizumab/Bevacizumab Treatment in Patients with Hepatocellular Carcinoma and Diabetes. Oncology Research. https://doi.org/10.32604/or.2026.073063

Vancouver

Dalbeni A, Vicardi M, Natola LA, Auriemma A, Stefanini B, Vivaldi C, et al. The Effect of Metformin on Atezolizumab/Bevacizumab Treatment in Patients with Hepatocellular Carcinoma and Diabetes. Oncology Research. 2026. doi:10.32604/or.2026.073063

BibTeX
@article{Dalbeni2026,
  author = {Dalbeni, Andrea and Vicardi, Marco and Natola, Leonardo A and Auriemma, Alessandra and Stefanini, Bernardo and Vivaldi, Caterina and Federico, Piera and Polloni, Andrea and Soldà, Caterina and Lani, Lorenzo and Garajová, Ingrid and Tamberi, Stefano and De Lorenzo, Stefania and Piscaglia, Fabio and Di Maria, Vincenzo and Masi, Gianluca and Lonardi, Sara and Brandi, Giovanni and Daniele, Bruno and Trevisani, Franco and Svegliati-Baroni, Gianluca and Schiada, Laura and Marra, Fabio and Campani, Claudia and Celsa, Ciro and Cabibbo, Giuseppe and Bruccoleri, Mariangela and Iavarone, Massimo and Stella, Leonardo and Ponziani, Francesca R and Pressiani, Tiziana and Rimassa, Lorenza and Tovoli, Francesco and Sacerdoti, David},
  title = {The Effect of Metformin on Atezolizumab/Bevacizumab Treatment in Patients with Hepatocellular Carcinoma and Diabetes},
  journal = {Oncology Research},
  year = {2026},
  doi = {10.32604/or.2026.073063}
}
Kostenlos starten →